ZURZUVAE (zuranolone)

About Sage Therapeutics

Sage Therapeutics' mission is to pioneer life-changing brain health medicines, achieving a landmark success with the first FDA-approved drug for postpartum depression, ZULRESSO. The company's strategy is built on a proprietary platform targeting GABA and NMDA receptors to develop rapid-onset therapies for mood and neurological disorders. While facing commercial challenges, Sage is advancing a promising pipeline and has implemented strategic partnerships and cost reductions to extend its runway and focus on high-value programs.

About Sage Therapeutics

Sage Therapeutics' mission is to pioneer life-changing brain health medicines, achieving a landmark success with the first FDA-approved drug for postpartum depression, ZULRESSO. The company's strategy is built on a proprietary platform targeting GABA and NMDA receptors to develop rapid-onset therapies for mood and neurological disorders. While facing commercial challenges, Sage is advancing a promising pipeline and has implemented strategic partnerships and cost reductions to extend its runway and focus on high-value programs.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals is a publicly traded CNS-focused biopharmaceutical company with a mission to improve patient lives through innovative neurology and psychiatry treatments. The company has successfully built a commercial foundation with eight marketed products and is advancing a pipeline featuring late-stage candidates for treatment-resistant depression and severe epilepsy. Its strategy combines internal R&D powered by proprietary drug delivery platforms with strategic acquisitions, such as Sage Therapeutics, to solidify its position as a comprehensive CNS therapeutics leader.

Therapeutic Areas

Other Postpartum Depression Drugs